Collegium Pharmaceutical Reports Strong Q4 & FY2025 Results, Reaffirms 2026 Guidance, and Repurchases $25M in Shares

summarizeSummary

Collegium Pharmaceutical announced robust fourth quarter and full-year 2025 financial results, driven by significant growth in Jornay PM revenue, and reaffirmed its positive 2026 financial guidance. The company also highlighted a strong cash position and $25 million in share repurchases.

check_boxKey Events

• Strong Q4 & FY2025 Financial Performance

  Reported Q4 net revenues of $205.4 million, up 13% year-over-year, and record full-year 2025 net revenues of $780.6 million, up 24% year-over-year. Adjusted EBITDA for Q4 was $127.3 million (up 18% YoY) and for FY2025 was $460.5 million (up 15% YoY).

• Jornay PM Drives Growth

  Jornay PM net revenue grew 57% year-over-year in Q4 to $45.9 million and 48% year-over-year for full-year 2025 to $148.9 million, reaching record prescription levels.

• 2026 Guidance Reaffirmed

  The company reaffirmed its full-year 2026 guidance, projecting product revenues of $805 million to $825 million and Jornay PM revenue of $190 million to $200 million.

• Strengthened Financial Position

  Ended 2025 with $386.7 million in cash, cash equivalents, and marketable securities. Successfully closed a new $980 million syndicated credit facility, improving debt terms, and repurchased $25 million in shares during 2025.

auto_awesomeAnalysis

The filing indicates strong operational performance for Collegium Pharmaceutical, with double-digit revenue growth for both the fourth quarter and full year 2025, significantly boosted by its ADHD treatment, Jornay PM. The reaffirmation of 2026 guidance, which projects continued growth, provides further confidence in the company's outlook. Additionally, the successful refinancing of debt and a substantial $25 million share repurchase program underscore a disciplined capital deployment strategy and a strengthened financial profile, which are positive signals for investors.